Cargando…
Development of a Model Care Pathway for Myasthenia Gravis
Myasthenia Gravis (MG) is a chronic, life-lasting condition that requires high coordination among different professionals and disciplines. The diagnosis of MG is often delayed and sometimes misdiagnosed. The goal of the care pathway (CP) is to add value to healthcare reducing unnecessary variations....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582978/ https://www.ncbi.nlm.nih.gov/pubmed/34770107 http://dx.doi.org/10.3390/ijerph182111591 |
_version_ | 1784597110478340096 |
---|---|
author | Payedimarri, Anil babu Ratti, Matteo Rescinito, Riccardo Vasile, Alessandra Seys, Deborah Dumas, Hervé Vanhaecht, Kris Panella, Massimiliano |
author_facet | Payedimarri, Anil babu Ratti, Matteo Rescinito, Riccardo Vasile, Alessandra Seys, Deborah Dumas, Hervé Vanhaecht, Kris Panella, Massimiliano |
author_sort | Payedimarri, Anil babu |
collection | PubMed |
description | Myasthenia Gravis (MG) is a chronic, life-lasting condition that requires high coordination among different professionals and disciplines. The diagnosis of MG is often delayed and sometimes misdiagnosed. The goal of the care pathway (CP) is to add value to healthcare reducing unnecessary variations. The quality of the care received by patients affected with MG could benefit from the use of CP. We conducted a study aimed to define an inclusive, comprehensive, and multidisciplinary CP for the diagnosis, treatment, and care of MG. The development of the model CP, key interventions, and process indicators is based on the literature review and 85 international MG experts were involved in their evaluation, expressing a judgment of relevance through the Delphi study. 60 activities are included in the model CP and evaluated by the MG experts were valid and feasible. The 60 activities were then translated into 14 key interventions and 24 process indicators. We believe that the developed model CP will help for MG patients to have a timely diagnosis and high-quality, accessible, and cost-effective treatments and care. We also believe that the development of model CPs for other rare diseases is feasible and could aid in the integration of evidence-based knowledge into clinical practice. |
format | Online Article Text |
id | pubmed-8582978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85829782021-11-12 Development of a Model Care Pathway for Myasthenia Gravis Payedimarri, Anil babu Ratti, Matteo Rescinito, Riccardo Vasile, Alessandra Seys, Deborah Dumas, Hervé Vanhaecht, Kris Panella, Massimiliano Int J Environ Res Public Health Article Myasthenia Gravis (MG) is a chronic, life-lasting condition that requires high coordination among different professionals and disciplines. The diagnosis of MG is often delayed and sometimes misdiagnosed. The goal of the care pathway (CP) is to add value to healthcare reducing unnecessary variations. The quality of the care received by patients affected with MG could benefit from the use of CP. We conducted a study aimed to define an inclusive, comprehensive, and multidisciplinary CP for the diagnosis, treatment, and care of MG. The development of the model CP, key interventions, and process indicators is based on the literature review and 85 international MG experts were involved in their evaluation, expressing a judgment of relevance through the Delphi study. 60 activities are included in the model CP and evaluated by the MG experts were valid and feasible. The 60 activities were then translated into 14 key interventions and 24 process indicators. We believe that the developed model CP will help for MG patients to have a timely diagnosis and high-quality, accessible, and cost-effective treatments and care. We also believe that the development of model CPs for other rare diseases is feasible and could aid in the integration of evidence-based knowledge into clinical practice. MDPI 2021-11-04 /pmc/articles/PMC8582978/ /pubmed/34770107 http://dx.doi.org/10.3390/ijerph182111591 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Payedimarri, Anil babu Ratti, Matteo Rescinito, Riccardo Vasile, Alessandra Seys, Deborah Dumas, Hervé Vanhaecht, Kris Panella, Massimiliano Development of a Model Care Pathway for Myasthenia Gravis |
title | Development of a Model Care Pathway for Myasthenia Gravis |
title_full | Development of a Model Care Pathway for Myasthenia Gravis |
title_fullStr | Development of a Model Care Pathway for Myasthenia Gravis |
title_full_unstemmed | Development of a Model Care Pathway for Myasthenia Gravis |
title_short | Development of a Model Care Pathway for Myasthenia Gravis |
title_sort | development of a model care pathway for myasthenia gravis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582978/ https://www.ncbi.nlm.nih.gov/pubmed/34770107 http://dx.doi.org/10.3390/ijerph182111591 |
work_keys_str_mv | AT payedimarrianilbabu developmentofamodelcarepathwayformyastheniagravis AT rattimatteo developmentofamodelcarepathwayformyastheniagravis AT rescinitoriccardo developmentofamodelcarepathwayformyastheniagravis AT vasilealessandra developmentofamodelcarepathwayformyastheniagravis AT seysdeborah developmentofamodelcarepathwayformyastheniagravis AT dumasherve developmentofamodelcarepathwayformyastheniagravis AT vanhaechtkris developmentofamodelcarepathwayformyastheniagravis AT panellamassimiliano developmentofamodelcarepathwayformyastheniagravis |